For the quarter ending 2025-09-30, ABUS has $97,710K in assets. $20,311K in debts. $22,408K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 22,408 | 37,412 | ||
| Investments in marketable short-term securities | 71,294 | 60,676 | ||
| Accounts receivable | 905 | 1,025 | ||
| Prepaid expenses and other current assets | 2,835 | 4,006 | ||
| Total current assets | 97,442 | 103,119 | ||
| Property and equipment, net of accumulated depreciation and impairment of 13,347 (december 31, 2024 12,996) | 137 | 148 | ||
| Right of use asset | 0 | 0 | ||
| Other non-current assets | 131 | 0 | ||
| Total assets | 97,710 | 103,267 | ||
| Accounts payable and accrued liabilities | 4,653 | 4,508 | ||
| Deferred license revenue, current | 0 | 0 | ||
| Lease liability, current | 531 | 514 | ||
| Total current liabilities | 5,184 | 5,022 | ||
| Liability related to sale of future royalties | 3,684 | 3,910 | ||
| Deferred license revenue, non-current | 0 | 0 | ||
| Contingent consideration | 11,052 | 10,784 | ||
| Lease liability, non-current | 391 | 575 | ||
| Total liabilities | 20,311 | 20,291 | ||
| Issued and outstanding 191,953,665 (december 31, 2024 189,963,492) | 1,418,560 | 1,417,110 | ||
| Additional paid-in capital | 83,285 | 82,628 | ||
| Deficit | -1,376,317 | -1,368,575 | ||
| Accumulated other comprehensive loss | -48,129 | -48,187 | ||
| Total stockholders equity | 77,399 | 82,976 | ||
| Total liabilities and stockholders equity | 97,710 | 103,267 | ||
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)